Udemy (UDMY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
The reported revenue represents a surprise of +1.69% over the Zacks Consensus Estimate of $196.56 million. With the consensus EPS estimate being $0.12, the EPS surprise was +33.33%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Udemy performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Enterprise Segment - Annual Recurring Revenue: $520 million versus the two-analyst average estimate of $516.6 million.
Consumer Segment - Monthly average buyers: 1.24 million versus 1.25 million estimated by two analysts on average.
Enterprise Segment - Total Customers: 17,107 versus the two-analyst average estimate of 17,330.
Revenue- Enterprise: $129.3 million versus $128.18 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +7.2% change.
Revenue- Consumer: $70.6 million compared to the $68.44 million average estimate based on two analysts. The reported number represents a change of -4.3% year over year.
View all Key Company Metrics for Udemy here>>>
Shares of Udemy have returned +0.2% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Udemy, Inc. (UDMY) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Wall Street thinks the party for Palantir can continue even after a wild rally in 2025 — but there's one key risk
Palantir is the top-performing stock in the S&P 500 this year, and Wall Street is upbeat about what's ahead. Palantir has been on a tear, climbing 113% since the start of the year. A lofty valuation is the main risk analysts are eyeing heading into second-quarter earnings. Wall Street thinks the Palantir party can keep going. The stock is already up by about 113% this year as it heads into its second-quarter earnings report after the bell on Monday, but analysts see reasons to believe the gains can pile up further. The Alex Karp-led software giant is benefiting from a slew of government contracts, roaring AI demand, and a cultlike following among retail investors in 2025. Shares of the company have soared from around $75 a share at the start of 2025 to above $160 on Monday. That ascent has made Palantir the best-performing stock in the S&P 500 this year. Analysts are bullish about Palantir's second-quarter earnings. They estimate the tech giant will report $939.3 million in revenue for the three-month period, up around 38% year over year. Here are some of the reasons they see the growth story continuing — and one key risk. 1. The AI trade is still running hot Palantir will likely keep up growth in its commercial segment, thanks to the ongoing hype surrounding AI. Accelerating AI adoption is creating a greater need to integrate data, which is good news for the stock, analysts at Mizuho wrote in a note. The bank said it conducted checks on Palantir's enterprise inbound activity, which gave it confidence that the company would be able to beat its commercial growth guidance in 2025. Palantir expects the US commercial side of its business to grow 68% for the year. "PLTR's recent execution and momentum is stunning, including material upward revisions across its commercial and government segments that we very much underestimated," Mizuho analysts wrote. Analysts at UBS said they also conducted checks on Palantir's enterprise businesses, and lifted their estimates for the company's revenue growth from 31% to 38% for the year. "We see potential tailwinds from the increasing adoption of AI across enterprise," Citi analysts wrote, adding that its checks and its conversation with Palantir's chief finance officer were also positive. Government contracts A large part of Palantir's growth story has been fueled by its contracts with the federal government. In April, the software company secured a $30 million deal with the US Immigration and Customs Enforcement for software to monitor visas and track deportations. In May, the firm teamed up with Fannie Mae, and said it would provide AI tools to support the government-sponsored mortgage financier's Crime Detection Unit. It also secured a $795 million contract with the Department of Defense's AI arm, and last week, locked a deal to help streamline the US Army for up to $10 billion for the next decade. The deal consolidates 75 existing contracts into a single agreement. "We believe this deal represents an additional tailwind for PLTR with AI initiatives across the US government accelerating with AI a strategic focus on the federal front and Palantir in the sweet spot to benefit from a tidal wave of federal spending on AI," analysts at Wedbush Securities wrote last week, calling Palantir one of the top tech stocks to own in 2025. "We remain positive on the public sector pipeline, which appears durable given ongoing geopolitical instability. Net, we believe PLTR will likely be able to continue growing its Government revenue >40% Y/Y over at least the near-term," Mizuho said. "We continue to view Palantir as well positioned to continue to deliver best-in-class growth given the secular trend towards enterprise AI adoption; the continued push for efficiency and technology adoption in the US government; and adoption of Operation Warp Speed among new defense entrants, traditional defense companies, and the broader manufacturing industry," analyst at Goldman Sachs wrote in a note following Palantir's first-quarter earnings report in May. High bar But there's one risk Wall Street is eyeing: the valuation is at eye-watering levels. As of Monday afternoon, the trailing 12-month price-to-earnings ratio was above 690x. Despite a bullish short-term outlook, Goldman Sachs, UBS, and Mizuho are among those on Wall Street who rated Palantir as "neutral" headed into its second-quarter earnings. Analysts at Citi, meanwhile, rated the stock as "Neutral/High Risk." "We maintain our Neutral/High Risk rating on the stock on valuation concerns and our view that second derivative/revision trends could moderate limiting upside," Citi added in a note. "That said, we are equally stunned by the multiple that PLTR has attained, which places its valuation dramatically above anything else in software," Mizuho analysts said, adding they would "continue to worry" that the stock could see a reversion sometime in the next several quarters. "We continue to be very impressed by the fundamental story (we have been since our launch) but valuation remains our key hurdle, we remain Neutral rated," UBS said. Read the original article on Business Insider Sign in to access your portfolio
CNBC
2 hours ago
- CNBC
CNBC Daily Open: Trump doubles down on criticism of jobs report — but markets bounce back
The U.S. Bureau of Labor Statistics' July's jobs report revised previous months' figures down so dramatically that U.S. President Donald Trump called it "RIGGED" and "CONCOCTED." Markets, however, seem to have shrugged off their worries for now — U.S. stocks rebounded Monday from the sell-off on Friday after the report was released. The move, however, could be more an instinctive reflex than a reflection of what's really driving markets. "Today is sort of a bounce-back day," said Sam Stovall, chief investment strategist at CFRA Research. "Stocks tend to pop after a drop, so that's what's happening." "We have to wait and see what happens tomorrow, because there could be a possibility that investors think, 'You know what, we really need to take some money off the table to digest some of these gains,'" he added. Trump's new tariffs come into force on Aug. 7, so there's a possibility investors could seize this opportunity, when markets have recovered slightly from Friday's losses, to take profit first — and before any further slowdown, as suggested by July's jobs report, is potentially "rigged" and strikes the U.S. economy. The EU will suspend its planned U.S. tariffs for six months. The countermeasures, which would have taken effect on Aug. 7, were delayed to allow the bloc to "further negotiate" with the U.S. and "finalise a Joint Statement" on their trade deal. Trump will 'substantially' raise tariffs on India. The South Asian country's oil purchases from Russia — a transaction defended by India's energy minister Hardeep Singh Puri — is the cause behind Trump's threat. Stocks rebound from Friday's losses. Major U.S. indexes rose Monday, with the S&P 500 snapping a four-day losing streak. The Stoxx Europe 600 gained 0.9%. Swiss stocks pared losses after the government said it would continue U.S. negotiations. Palantir's quarterly revenue exceeds $1 billion. Wall Street had expected the software provider to hit that milestone only in the fourth quarter of the year. But a 48% year-over-year jump in second-quarter revenue helped Palantir beat forecasts. [PRO] The "Magnificent Seven" are powering earnings growth. Year on year, Mag 7 earnings have increased by 26%. The other S&P 500 companies posted a combined 4% growth — a disparity that could be problematic for investors, according to an analyst. Contentious July jobs report confirms the U.S. economy is slowing sharply. Here's why Nonfarm payrolls rose by just 73,000 in July, below even the muted expectations. Heavy downward revisions to the May and June count took the three-month average job gains down to just 35,000, or less than one-third the pace for the same period a year ago. Traditionally a lagging indicator when it comes to recessions, the weakness in job growth points to an economy that may be slowing even more than some of the traditional metrics are showing.
Business Upturn
2 hours ago
- Business Upturn
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB
– Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis – KUALA LUMPUR, Malaysia, Aug. 04, 2025 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; 'Cyclacel' or the 'Company'), a biopharmaceutical company developing innovative cancer medicines, highlighted a preclinical study from independent investigators titled, ' Evaluation of antitumor effects of plogosertib, PLK1 inhibitor in biliary tract cancer with BUBR1 as a potential biomarker ' in the journal, Cancer Research, previously reported in a poster at the American Association of Cancer Research 2025 annual meeting.1 The investigators found that several BTC cancer cell lines were sensitive to plogosertib both as monotherapy and in combinations. Consistently with its antimitotic mechanism of action, plogosertib promoted mitotic checkpoint complex (MCC) formation in prometaphase, which induced mitotic arrest resulting in apoptosis of BTC cells. The authors have also found that BUBR1, a critical mitotic checkpoint protein, may be useful as a biomarker to assess plogosertib's effectiveness. BTC cells with high BUBR1 expression were found to be more sensitive to plogosertib compared to those with low expression. The study concluded that BTC cells with high BUBR1 expression are sensitive to the PLK1 inhibitor plogosertib that demonstrate synergistic effects when combined with an ATR inhibitor, which suggest that targeting PLK1 could be an effective strategy for BTC treatment, especially with BUBR1 expression as a potential biomarker to inform optimal combination therapies. About Biliary Tract Cancer (BTC) BTC, also called cholangiocarcinoma, is a rare but aggressive cancer occurring in the biliary tract, a network of small tubes, or ducts, connecting the liver, gallbladder and small intestine. According to estimates from the National Cancer Institute's SEER database annual US incidence of BTC is 4.4 per 100,000. Prognosis for BTC patients is poor with 5-year overall survival of approximately 10–40% even after surgical tumor resection. BTC treatment strategies include chemotherapy, surgery, radiation and targeted medicines depending on location and stage. As these approaches are not curative, there is an urgent, unmet medical need to treat patients with relapsed, refractory and/or unresectable BTC. About Polo-like Kinase and Plogosertib Polo-like kinase 1 (PLK1) is a serine/threonine kinase that plays a central role in cell division or mitosis. PLK1 is an important regulator of the DNA damage cell cycle checkpoint, mitotic entry and exit, spindle formation and cytokinesis, or cell separation into daughter cells. In general, cancer cells, and in particular KRAS mutated and p53(-) cells, are very sensitive to PLK1 depletion. In contrast normal cells with intact cell cycle checkpoints are less sensitive. Pharmacological inhibition of PLK1 in cancer cells blocks proliferation by prolonged mitotic arrest and induces onset of apoptotic death of such cells. Plogosertib (formerly CYC140) is a novel, small molecule, selective and potent PLK1 inhibitor. It has demonstrated impressive efficacy in human tumor xenografts at nontoxic doses. Cyclacel's translational biology program supports the development of plogosertib in solid tumors and leukemias. Preclinical data from independent groups have shown that certain ARID1A- and/or SMARCA-mutated cancers, and cancers associated with DNAJ-PKAc fusions, may benefit from treatment with plogosertib. Additionally, recent data suggest that PLK1 inhibition may be effective in KRAS-mutated metastatic colorectal cancer. PLK1 overexpression correlates with poor patient prognosis in several tumors, including biliary tract, esophageal, fibrolamellar liver, gastric, leukemia, lung, ovarian, and squamous cell cancers, as well as MYC-amplified cancers. Initial dose escalation data from a Phase 1 clinical study of oral plogosertib suggest that the compound is well tolerated with no dose limiting toxicity observed in five dosing schedules. Clinical benefit was observed in patients with adenoid cystic, biliary tract, ovarian, and squamous cell sinus cancers. About Cyclacel Pharmaceuticals, Inc. Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle and mitosis biology. The anti-mitotic program is evaluating plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit Forward-looking Statements This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended and the Safe Harbor provisions of the US Private Securities Litigation Reform Act of 1995, and encompasses all statements, other than statements of historical fact contained in this press release. These forward-looking statements can be identified by terminology such as 'may,' 'could,' 'will,' 'expects,' 'anticipates,' 'aims,' 'future,' 'intends,' 'plans,' 'believes,' 'estimates,' 'targets,' 'likely to', 'understands' and similar statements. These forward-looking statements are based on management's current expectations. However, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. These statements are neither promises nor guarantees but involve known and unknown risks, uncertainties and other important factors and circumstances that may cause Cyclacel's actual results, performance or achievements to be materially different from its expectations expressed or implied by the forward-looking statements, including conditions in the U.S. capital markets, negative global economic conditions, potential negative developments resulting from epidemics or natural disasters, other negative developments in Cyclacel's business or unfavorable legislative or regulatory developments. We caution you therefore against relying on these forward-looking statements, and we qualify all of our forward-looking statements by these cautionary statements. For a discussion of additional factors that may affect the outcome of such forward-looking statements, see our 2024 annual report on Form 10-K, and in particular the 'Risk Factors' section, as well as the other documents filed with or furnished to the SEC by Cyclacel from time to time. Copies of these filings are available online from the SEC at or on the SEC Filings section of our Investor Relations website at These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. These forward-looking statements should not be relied upon as representing Cyclacel's views as of any date subsequent to the date of this press release. All forward-looking statements in this press release are based on information currently available to Cyclacel, and Cyclacel and its authorized representatives assume no obligation to update these forward-looking statements in light of new information or future events. Accordingly, undue reliance should not be placed upon the forward-looking statements. Contact Cyclacel Pharmaceuticals, Inc. Email: [email protected] © Copyright 2025 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc. SOURCE: Cyclacel Pharmaceuticals, Inc. 1 Yoojin Jeong, Yoojin Jeong, et al, Abstract 5406: Evaluation of antitumor effects of plogosertib, PLK1 inhibitor in biliary tract cancer with BUBR1 as a potential biomarker, Cancer Res (2025) 85 (8 Supplement 1): 5406. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
